Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals, Inc. - common stock
(NQ:
MIRM
)
80.45
+1.20 (+1.51%)
Delayed Quote
Updated: 11:05 AM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals, Inc. - common stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
↗
July 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...
Via
Benzinga
Mirum Pharma Out-Licenses Maralixibat Rights To GC Pharma in South Korea
↗
July 27, 2021
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and GC Pharma have entered into an exclusive licensing agreement to develop and commercialize Mirum's maralixibat...
Via
Benzinga
Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea
July 26, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present at Piper Sandler’s Virtual EASL Takeaway Day
June 24, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021
June 23, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021
June 16, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors
June 07, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting
June 03, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021
May 26, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
May 06, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
↗
May 01, 2021
CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million...
Via
Talk Markets
Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
April 29, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
April 29, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome
April 26, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
April 12, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
